Wang et al (Nat Med 2025 Jan 7; https://doi.org/10.1038/s41591-024-03419-3) carried out a placebo-controlled, randomized, part 3 trial to judge the security and efficacy of suraxavir marboxil, an oral inhibitor of influenza polymerase acidic protein (PA), in acute uncomplicated influenza. Practically 600 outpatients aged 5 to 65 years got a single dose of suraxavir or placebo inside 2 days of symptom onset. Suraxavir decreased the median time to alleviation of signs by over 20 hours and decreased viral load inside 24 hours as in comparison with placebo.
Trending Merchandise
Added to wishlistRemoved from wishlist 0
$25.00
Added to wishlistRemoved from wishlist 0
$29.71
Added to wishlistRemoved from wishlist 0
$32.99
Added to wishlistRemoved from wishlist 0
$13.99
Added to wishlistRemoved from wishlist 0
$17.99
Added to wishlistRemoved from wishlist 0
$7.85
Added to wishlistRemoved from wishlist 0
$8.83
Added to wishlistRemoved from wishlist 0
$45.40
Added to wishlistRemoved from wishlist 0
$9.99
Carlyle Cat’s Claw Capsules 1000mg | 180 Count | Uncaria Tomentosa | Non-GMO, Gluten Free Supplement
Added to wishlistRemoved from wishlist 0
$15.28